Silarus Therapeutics Inc.

GlaxoSmithKline PLC 's six-year old drug development collaboration with Avalon Ventures has resulted in a single acquisition by GSK. The companies announced on 11 September that GSK will buy Sitari P

The joint venture announced by GlaxoSmithKline PLC and Avalon Ventures in April 2013 continues to bear fruit at a rapid pace, as the partners announced the founding of three new single-program bio

SAN FRANCISCO — The “build-to-buy” biotech partnering model is still a viable business strategy, even amid the economic rebound, big pharma and venture capital execs said at the recent CALBIO meeting.

It hasn’t even been two years since GlaxoSmithKline PLC and San Diego-based venture capital firm Avalon Ventures announced a partnership to fund up to 10 early-stage life science companies driven